Last reviewed · How we verify
Hydroxychloroquine in combination of Azithromycin
Hydroxychloroquine in combination of Azithromycin is a Antimalarial + Macrolide antibiotic combination Small molecule drug developed by Sheba Medical Center. It is currently in Phase 3 development for COVID-19 (investigational, Phase 3).
Hydroxychloroquine inhibits viral entry and endosomal acidification while azithromycin provides antimicrobial and immunomodulatory effects, together targeting viral replication and inflammatory response.
Hydroxychloroquine inhibits viral entry and endosomal acidification while azithromycin provides antimicrobial and immunomodulatory effects, together targeting viral replication and inflammatory response. Used for COVID-19 (investigational, Phase 3).
At a glance
| Generic name | Hydroxychloroquine in combination of Azithromycin |
|---|---|
| Sponsor | Sheba Medical Center |
| Drug class | Antimalarial + Macrolide antibiotic combination |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
Hydroxychloroquine is a quinoline antimalarial that raises endosomal pH and inhibits toll-like receptor signaling, potentially blocking viral entry and reducing inflammatory cytokine production. Azithromycin is a macrolide antibiotic with immunomodulatory properties that can reduce pro-inflammatory cytokine release. The combination was investigated for synergistic antiviral and anti-inflammatory effects.
Approved indications
- COVID-19 (investigational, Phase 3)
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- QT prolongation
- Retinopathy (hydroxychloroquine, long-term)
- Headache
Key clinical trials
- Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants (PHASE2)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (PHASE3)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients (PHASE2)
- Treatment for COVID-19 in High-Risk Adult Outpatients (PHASE2, PHASE3)
- Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxychloroquine in combination of Azithromycin CI brief — competitive landscape report
- Hydroxychloroquine in combination of Azithromycin updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI
Frequently asked questions about Hydroxychloroquine in combination of Azithromycin
What is Hydroxychloroquine in combination of Azithromycin?
How does Hydroxychloroquine in combination of Azithromycin work?
What is Hydroxychloroquine in combination of Azithromycin used for?
Who makes Hydroxychloroquine in combination of Azithromycin?
What drug class is Hydroxychloroquine in combination of Azithromycin in?
What development phase is Hydroxychloroquine in combination of Azithromycin in?
What are the side effects of Hydroxychloroquine in combination of Azithromycin?
Related
- Drug class: All Antimalarial + Macrolide antibiotic combination drugs
- Manufacturer: Sheba Medical Center — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Immunology
- Indication: Drugs for COVID-19 (investigational, Phase 3)
- Compare: Hydroxychloroquine in combination of Azithromycin vs similar drugs
- Pricing: Hydroxychloroquine in combination of Azithromycin cost, discount & access